1. Home
  2. GNLX vs RZLT Comparison

GNLX vs RZLT Comparison

Compare GNLX & RZLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Genelux Corporation

GNLX

Genelux Corporation

HOLD

Current Price

$2.48

Market Cap

110.4M

Sector

Health Care

ML Signal

HOLD

Logo Rezolute Inc. (NV)

RZLT

Rezolute Inc. (NV)

HOLD

Current Price

$3.99

Market Cap

420.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
GNLX
RZLT
Founded
2001
2010
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
110.4M
420.8M
IPO Year
2022
2011

Fundamental Metrics

Financial Performance
Metric
GNLX
RZLT
Price
$2.48
$3.99
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
4
6
Target Price
★ $17.25
$9.67
AVG Volume (30 Days)
266.4K
★ 1.3M
Earning Date
05-12-2026
05-13-2026
Dividend Yield
N/A
N/A
EPS Growth
9.47
★ 23.47
EPS
★ N/A
N/A
Revenue
★ $8,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.29
$1.07
52 Week High
$8.54
$11.46

Technical Indicators

Market Signals
Indicator
GNLX
RZLT
Relative Strength Index (RSI) 44.65 40.49
Support Level $2.34 $3.69
Resistance Level $2.86 $5.36
Average True Range (ATR) 0.14 0.25
MACD 0.01 -0.01
Stochastic Oscillator 39.29 40.11

Price Performance

Historical Comparison
GNLX
RZLT

About GNLX Genelux Corporation

Genelux Corp is a late-stage biopharmaceutical firm focused on developing oncolytic viral immunotherapies for cancer. Its pipeline includes clinical and preclinical candidates designed to target tumor cells and stimulate an immune response against tumor-specific antigens. The company is focused on the development of next-generation oncolytic viral immunotherapies that are designed to generate a personalized multi-prong attack to overwhelm a tumor's sophisticated defense mechanisms.

About RZLT Rezolute Inc. (NV)

Rezolute Inc is a clinical-stage biopharmaceutical company focused on developing therapies for rare and metabolic diseases. The company aims to address unmet medical needs in conditions like congenital hyperinsulinism, a rare endocrine disorder causing excessive insulin production and resulting hypoglycemia. Rezolute's pipeline includes drug candidates designed to improve patient outcomes while reducing treatment burdens. The company engages in research, development, and clinical trials to advance its therapies and collaborates with medical communities and patient groups to support its objectives. Revenue and value creation depend largely on successful product development and regulatory approvals.

Share on Social Networks: